Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection -

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection
Information type: Randomised controlled trials
Source: The Lancet HIV
Specialities: Infection and infectious diseases | Sexual health
Summary
RCT (n=645) reports at week 96, HIV-1 RNA<50copies/mL was achieved by 84% of participants in the bictegravir group vs 86% in the dolutegravir group (difference −2.3%), demonstrating non-inferiority of the bictegravir regimen compared with the dolutegravir regimen.
UKMi comment
Whilst this study compares bictegravir directly with dolutegravir (given that the same emtricitabine plus tenofovir alafenamide backbone is used in both groups) a separate study also published early online in the Lancet HIV presents 96 week data on bictegravir in a fixed-dose combination with emtricitabine and tenofovir alafenamide versus fixed-dose dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1.
Related links: Editorial